Holen Sie sich die Stockscreener-App
10.71
1.79%
-0.195
Handel nachbörslich:
10.72
0.005
+0.05%
Schlusskurs vom Vortag:
$10.91
Offen:
$10.89
24-Stunden-Volumen:
1.32M
Relative Volume:
1.23
Marktkapitalisierung:
$1.05B
Einnahmen:
$47.56M
Nettoeinkommen (Verlust:
$-156.83M
KGV:
-5.1514
EPS:
-2.08
Netto-Cashflow:
$-127.98M
1W Leistung:
-34.26%
1M Leistung:
-21.01%
6M Leistung:
-30.83%
1J Leistung:
-0.79%
1-Tages-Spanne:
$10.44
$11.01
1-Wochen-Bereich:
$10.44
$15.27
52-Wochen-Spanne:
$10.44
$19.09
Avadel Pharmaceuticals Plc Stock (AVDL) Company Profile
Vergleichen Sie AVDL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| AVDL | 10.71 | 1.05B | 47.56M | -156.83M | -127.98M | -2.08 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Avadel Pharmaceuticals Plc Stock (AVDL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-12 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-05 | Bestätigt | H.C. Wainwright | Buy |
| 2024-03-05 | Bestätigt | Needham | Buy |
| 2024-03-05 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2022-11-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-28 | Fortgesetzt | Craig Hallum | Buy |
| 2022-05-26 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2020-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2020-07-21 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-03 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Eingeleitet | Stifel | Buy |
| 2020-02-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-01-30 | Eingeleitet | Craig Hallum | Buy |
| 2019-06-14 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-02-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
Alle ansehen
Avadel Pharmaceuticals Plc Aktie (AVDL) Neueste Nachrichten
Short Interest in Avadel Pharmaceuticals plc (NASDAQ:AVDL) Declines By 7.3% - MarketBeat
What is HC Wainwright’s Estimate for AVDL FY2024 Earnings? - Defense World
Idiopathic Hypersomnia Treatment Market will experience - openPR
HC Wainwright Issues Pessimistic Forecast for AVDL Earnings - MarketBeat
What is Lifesci Capital's Forecast for AVDL FY2024 Earnings? - MarketBeat
Leerink Partnrs Has Negative Outlook of AVDL FY2024 Earnings - MarketBeat
Avadel Pharmaceuticals plc (AVDL) Outlook: Looking Back For Insights - Stocks Register
Janus Henderson Group's Strategic Acquisition of Avadel Pharmace - GuruFocus.com
FY2025 Earnings Estimate for AVDL Issued By Leerink Partnrs - MarketBeat
Avadel Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance UK
Avadel shares price target cut, maintains buy on Q3 results By Investing.com - Investing.com Nigeria
Polar Capital Holdings Plc's Strategic Reduction in Avadel Pharm - GuruFocus.com
Avadel Pharmaceuticals PLC (AVDL) Shares Down 7.38% on Nov 13 - GuruFocus.com
Avadel Pharmaceuticals (NASDAQ:AVDL) Announces Earnings Results - MarketBeat
Avadel Pharmaceuticals (NASDAQ:AVDL) Stock Price Down 3.9% After Analyst Downgrade - MarketBeat
Avadel Pharmaceuticals (NASDAQ:AVDL) Price Target Lowered to $25.00 at HC Wainwright - MarketBeat
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2024 Earnings Call Transcript - Insider Monkey
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference - The Manila Times
Avadel Pharmaceuticals to Present at Jefferies London Healthcare Conference | AVDL Stock News - StockTitan
Avadel Pharmaceuticals plc (AVDL) Quarterly 10-Q Report - Quartzy
Avadel Pharmaceuticals Reports Strong Growth with LUMRYZ - TipRanks
Avadel: Q3 Earnings Snapshot - Houston Chronicle
Avadel Pharmaceuticals PLC (AVDL) Stock Price Down 15.83% on Nov 12 - GuruFocus.com
Avadel Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Avadel Pharmaceuticals' (AVDL) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Avadel's LUMRYZ Sales Surge to $50M as Patient Base Grows 44% in Q3 | AVDL Stock News - StockTitan
Avadel Pharmaceuticals PLC (AVDL) Q3 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Learn to Evaluate (AVDL) using the Charts - Stock Traders Daily
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Avadel Pharmaceuticals (AVDL) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12 - The Manila Times
Avadel Pharmaceuticals (NASDAQ:AVDL) Earns “Buy” Rating from Needham & Company LLC - Defense World
Oppenheimer Forecasts Strong Price Appreciation for Avadel Pharmaceuticals (NASDAQ:AVDL) Stock - Defense World
Avadel Pharmaceuticals’ (AVDL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Court Denies Jazz’s Challenge of Avadel’s Orphan Drug Lumryz - Sleep Review
US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle - Yahoo Finance
Loss-Making Avadel Pharmaceuticals plc (NASDAQ:AVDL) Expected To Breakeven In The Medium-Term - Yahoo Finance
Avadel Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:AVDL) - Defense World
Court upholds FDA approval of Avadel's narcolepsy drug LUMRYZ By Investing.com - Investing.com South Africa
Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Gap UpStill a Buy? - MarketBeat
Court upholds FDA approval of Avadel's narcolepsy drug LUMRYZ - Investing.com
Avadel Pharma Shares Rise on Favorable Ruling for FDA in Lumryz Litigation - Marketscreener.com
Shares Rally Up For Avadel (AVDL) As Court Rules Favorably - Stocks Telegraph
Needham & Company LLC Reiterates "Buy" Rating for Avadel Pharmaceuticals (NASDAQ:AVDL) - MarketBeat
Avadel soars after court rules in favor of FDA in Lumryz case with Jazz Pharma - MSN
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation - The Manila Times
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares Bought by Iridian Asset Management LLC CT - MarketBeat
Trend Tracker for (AVDL) - Stock Traders Daily
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Short Interest Update - MarketBeat
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz - MSN
Finanzdaten der Avadel Pharmaceuticals Plc-Aktie (AVDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):